Caris Life Sciences Launches Caris ChromoSeq Whole Genome Sequencing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 02 2026
0mins
Should l Buy CAI?
Caris Life Sciences announced the launch of Caris ChromoSeq, a Whole Genome Sequencing and Whole Transcriptome assay designed to support the comprehensive clinical genomic evaluation of myeloid malignancies. The test is intended for use in acute myeloid leukemia, or AML, myelodysplastic syndromes, or MDS, and myeloproliferative neoplasms, or MPN, as well as in patients with suspected myeloid malignancies characterized by unexplained cytopenia persisting for more than four months, where other potential causes have been reasonably excluded. Caris ChromoSeq can replace the multiple test protocols of the myeloid diagnostic workflow, complementing the clinician's overall clinical and pathological evaluation. The test delivers approximately 250x read depth across the genome with 40 million transcriptome read. Results are synthesized into a single report to support clinical decision-making, with an expected seven-day turnaround time.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CAI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CAI
Wall Street analysts forecast CAI stock price to rise
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 20.950
Low
30.00
Averages
36.17
High
40.00
Current: 20.950
Low
30.00
Averages
36.17
High
40.00
About CAI
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Caris Life Sciences Advances Access to Cancer Clinical Trials Nationwide
- Access Gap in Trials: Research indicates that 70% of U.S. counties lack active cancer treatment trials, leaving nearly one in five Americans aged 55 and older without local access to investigational therapies; Caris's RIT solution aims to bridge this gap by deploying trials directly to community oncology practices.
- Increased Patient Participation: A meta-analysis in the Journal of the National Cancer Institute found that 55% of cancer patients offered a trial agree to participate, suggesting that access and infrastructure, rather than patient willingness, are the main barriers, which Caris addresses through rapid molecular profiling and trial matching.
- Integrated Technology Advantage: The Caris RIT solution integrates comprehensive molecular profiling, automated trial matching, and streamlined site activation, ensuring that patients can transition from molecular analysis to trial enrollment in approximately two weeks, significantly enhancing treatment accessibility.
- Data-Driven Decision Making: As of December 31, 2025, Caris has established over 1.016 million molecular tumor profiles and 740,000 matched profiles, supporting clinical decision-making and driving the standardization of precision medicine, ensuring every cancer patient receives a treatment plan informed by their molecular profile.
See More
Caris Life Sciences Advances Access to Cancer Clinical Trials Nationwide
- Clinical Trial Access Gap: Research indicates that 70% of U.S. counties lack active cancer treatment trials, leaving nearly one in five Americans aged 55 and older without local access to investigational therapies; Caris's RIT solution aims to bridge this gap by deploying trials directly to community oncology practices.
- Increased Patient Participation: Among cancer patients offered trials, 55% agree to participate, suggesting that the main barriers are access and infrastructure rather than patient willingness; Caris's rapid molecular profiling and trial matching are expected to significantly enhance patient enrollment rates.
- Rapid Trial Matching: The RIT solution can move from molecular profiling to patient enrollment in approximately two weeks, and as quickly as five days, ensuring patients receive care locally while minimizing the burden of long-distance travel, thereby improving their treatment experience.
- Extensive Database Support: As of December 31, 2025, Caris has established over 1.016 million molecular tumor profiles and 740,000 matched profiles, facilitating precise trial matching and advancing the adoption of precision medicine to ensure every cancer patient receives treatment informed by their molecular profile.
See More
Caris Launches AI-Driven NSCLC Treatment Selection Signature
- AI-Driven Treatment Selection: Caris Life Sciences has launched an AI-driven molecular insight for non-small cell lung cancer (NSCLC) patients eligible for mono-immunotherapy, aiming to enhance survival rates by integrating whole exome and transcriptome sequencing data to guide physicians in chemotherapy decisions.
- Advancement in Precision Medicine: The newly developed NSCLC immunotherapy selection signature utilizes machine learning to identify complex molecular signatures, stratifying patients into high-risk and standard-risk groups, thereby predicting which patients may benefit from chemotherapy and reducing unnecessary exposure, significantly improving patient treatment experiences.
- Innovation in Clinical Application: The introduction of this signature not only provides physicians with a unique molecular signature for more scientifically informed treatment decisions but also underscores the importance of personalized treatment strategies, marking Caris's ongoing innovation in the field of precision oncology.
- FDA Approval Context: Caris received FDA approval for MI Cancer Seek in November 2024, becoming the first assay to simultaneously utilize whole exome and transcriptome sequencing as a companion diagnostic tool, further solidifying its leadership position in molecular oncology.
See More
Caris Launches AI-Driven Molecular Insights for Lung Cancer Treatment
- Breakthrough in Precision Treatment: Caris Life Sciences has launched AI-driven molecular insights for non-small cell lung cancer (NSCLC) patients, aiming to enhance survival rates by integrating whole exome and transcriptome sequencing data to assist physicians in making more precise immunotherapy and chemotherapy combination choices.
- Clinical Decision Support: The newly developed treatment selection signature identifies which patients may benefit from chemotherapy and which may be harmed, significantly reducing unnecessary chemotherapy exposure and improving patient treatment experiences and quality of life.
- Data-Driven Personalized Medicine: This signature leverages Caris's large-scale clinico-genomic datasets and employs machine learning to identify complex molecular signatures, moving beyond traditional small panel biomarker tests to provide more biologically guided treatment options.
- Enhanced Industry Impact: Caris's innovation not only offers new treatment options for NSCLC patients but also further solidifies its leadership position in the precision medicine field, demonstrating its commitment to transforming healthcare.
See More
Caris Launches Advanced Whole Genome Sequencing Technology
- Technological Innovation: Caris Life Sciences has launched Caris ChromoSeq™, a Whole Genome and Whole Transcriptome Sequencing assay designed to provide comprehensive clinical genomic evaluations for myeloid malignancies, which is expected to significantly enhance diagnostic efficiency.
- Enhanced Data Depth: The assay delivers approximately 250x read depth across the genome and 40 million transcriptome reads, enabling higher genomic resolution from bone marrow aspirates or peripheral blood samples, thereby accelerating the clinical decision-making process.
- Simplified Reporting: Caris ChromoSeq integrates multiple test results into a single, easy-to-interpret report, with an expected turnaround time of seven days, helping physicians make rapid treatment decisions and reducing patient wait times.
- Market Outlook: The launch of this technology underscores Caris's ongoing commitment to precision medicine, aiming to support clinicians by simplifying complexity and advancing the diagnosis and treatment of hematological cancers.
See More
Caris Launches Advanced Whole Genome and Transcriptome Sequencing Technology
- Technological Innovation: Caris Life Sciences has launched Caris ChromoSeq™, a Whole Genome Sequencing and Whole Transcriptome Sequencing assay designed to provide comprehensive clinical genomic evaluations for myeloid malignancies, which is expected to significantly enhance diagnostic efficiency.
- Enhanced Data Depth: The test delivers approximately 250x read depth across the genome and 40 million transcriptome reads, enabling higher genomic resolution from bone marrow or peripheral blood samples, thereby accelerating clinical decision-making.
- Streamlined Diagnostic Process: Caris ChromoSeq can replace traditional multiple testing protocols, consolidating results into a single, easy-to-interpret report with an expected turnaround time of seven days, assisting physicians in making rapid treatment decisions that improve patient outcomes.
- Strategic Implications: This technology launch underscores Caris's ongoing commitment to precision medicine, aiming to simplify complexity through innovative molecular profiling technologies that support clinicians in their decision-making processes across the cancer care continuum.
See More
Caris Life Sciences Advances Access to Cancer Clinical Trials Nationwide
- Access Gap in Trials: Research indicates that 70% of U.S. counties lack active cancer treatment trials, leaving nearly one in five Americans aged 55 and older without local access to investigational therapies; Caris's RIT solution aims to bridge this gap by deploying trials directly to community oncology practices.
- Increased Patient Participation: A meta-analysis in the Journal of the National Cancer Institute found that 55% of cancer patients offered a trial agree to participate, suggesting that access and infrastructure, rather than patient willingness, are the main barriers, which Caris addresses through rapid molecular profiling and trial matching.
- Integrated Technology Advantage: The Caris RIT solution integrates comprehensive molecular profiling, automated trial matching, and streamlined site activation, ensuring that patients can transition from molecular analysis to trial enrollment in approximately two weeks, significantly enhancing treatment accessibility.
- Data-Driven Decision Making: As of December 31, 2025, Caris has established over 1.016 million molecular tumor profiles and 740,000 matched profiles, supporting clinical decision-making and driving the standardization of precision medicine, ensuring every cancer patient receives a treatment plan informed by their molecular profile.
See More
Caris Life Sciences Advances Access to Cancer Clinical Trials Nationwide
- Clinical Trial Access Gap: Research indicates that 70% of U.S. counties lack active cancer treatment trials, leaving nearly one in five Americans aged 55 and older without local access to investigational therapies; Caris's RIT solution aims to bridge this gap by deploying trials directly to community oncology practices.
- Increased Patient Participation: Among cancer patients offered trials, 55% agree to participate, suggesting that the main barriers are access and infrastructure rather than patient willingness; Caris's rapid molecular profiling and trial matching are expected to significantly enhance patient enrollment rates.
- Rapid Trial Matching: The RIT solution can move from molecular profiling to patient enrollment in approximately two weeks, and as quickly as five days, ensuring patients receive care locally while minimizing the burden of long-distance travel, thereby improving their treatment experience.
- Extensive Database Support: As of December 31, 2025, Caris has established over 1.016 million molecular tumor profiles and 740,000 matched profiles, facilitating precise trial matching and advancing the adoption of precision medicine to ensure every cancer patient receives treatment informed by their molecular profile.
See More
Caris Launches AI-Driven NSCLC Treatment Selection Signature
- AI-Driven Treatment Selection: Caris Life Sciences has launched an AI-driven molecular insight for non-small cell lung cancer (NSCLC) patients eligible for mono-immunotherapy, aiming to enhance survival rates by integrating whole exome and transcriptome sequencing data to guide physicians in chemotherapy decisions.
- Advancement in Precision Medicine: The newly developed NSCLC immunotherapy selection signature utilizes machine learning to identify complex molecular signatures, stratifying patients into high-risk and standard-risk groups, thereby predicting which patients may benefit from chemotherapy and reducing unnecessary exposure, significantly improving patient treatment experiences.
- Innovation in Clinical Application: The introduction of this signature not only provides physicians with a unique molecular signature for more scientifically informed treatment decisions but also underscores the importance of personalized treatment strategies, marking Caris's ongoing innovation in the field of precision oncology.
- FDA Approval Context: Caris received FDA approval for MI Cancer Seek in November 2024, becoming the first assay to simultaneously utilize whole exome and transcriptome sequencing as a companion diagnostic tool, further solidifying its leadership position in molecular oncology.
See More
Caris Launches AI-Driven Molecular Insights for Lung Cancer Treatment
- Breakthrough in Precision Treatment: Caris Life Sciences has launched AI-driven molecular insights for non-small cell lung cancer (NSCLC) patients, aiming to enhance survival rates by integrating whole exome and transcriptome sequencing data to assist physicians in making more precise immunotherapy and chemotherapy combination choices.
- Clinical Decision Support: The newly developed treatment selection signature identifies which patients may benefit from chemotherapy and which may be harmed, significantly reducing unnecessary chemotherapy exposure and improving patient treatment experiences and quality of life.
- Data-Driven Personalized Medicine: This signature leverages Caris's large-scale clinico-genomic datasets and employs machine learning to identify complex molecular signatures, moving beyond traditional small panel biomarker tests to provide more biologically guided treatment options.
- Enhanced Industry Impact: Caris's innovation not only offers new treatment options for NSCLC patients but also further solidifies its leadership position in the precision medicine field, demonstrating its commitment to transforming healthcare.
See More
Caris Launches Advanced Whole Genome Sequencing Technology
- Technological Innovation: Caris Life Sciences has launched Caris ChromoSeq™, a Whole Genome and Whole Transcriptome Sequencing assay designed to provide comprehensive clinical genomic evaluations for myeloid malignancies, which is expected to significantly enhance diagnostic efficiency.
- Enhanced Data Depth: The assay delivers approximately 250x read depth across the genome and 40 million transcriptome reads, enabling higher genomic resolution from bone marrow aspirates or peripheral blood samples, thereby accelerating the clinical decision-making process.
- Simplified Reporting: Caris ChromoSeq integrates multiple test results into a single, easy-to-interpret report, with an expected turnaround time of seven days, helping physicians make rapid treatment decisions and reducing patient wait times.
- Market Outlook: The launch of this technology underscores Caris's ongoing commitment to precision medicine, aiming to support clinicians by simplifying complexity and advancing the diagnosis and treatment of hematological cancers.
See More
Caris Launches Advanced Whole Genome and Transcriptome Sequencing Technology
- Technological Innovation: Caris Life Sciences has launched Caris ChromoSeq™, a Whole Genome Sequencing and Whole Transcriptome Sequencing assay designed to provide comprehensive clinical genomic evaluations for myeloid malignancies, which is expected to significantly enhance diagnostic efficiency.
- Enhanced Data Depth: The test delivers approximately 250x read depth across the genome and 40 million transcriptome reads, enabling higher genomic resolution from bone marrow or peripheral blood samples, thereby accelerating clinical decision-making.
- Streamlined Diagnostic Process: Caris ChromoSeq can replace traditional multiple testing protocols, consolidating results into a single, easy-to-interpret report with an expected turnaround time of seven days, assisting physicians in making rapid treatment decisions that improve patient outcomes.
- Strategic Implications: This technology launch underscores Caris's ongoing commitment to precision medicine, aiming to simplify complexity through innovative molecular profiling technologies that support clinicians in their decision-making processes across the cancer care continuum.
See More
